All In Biotech

Drug Trial Radar · NCT01986101

A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression.

Last checked: Nov 20, 2026Latest source record: Apr 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 525 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

525

Actual

Start

Feb 19, 2014

Primary completion

Feb 1, 2017

Study completion Feb 16, 2017

Sponsor

Lead sponsor
Sumitomo Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 18, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.

Conditions

  • Bipolar Depression

Interventions

  • PlaceboDrug

    Placebo comparator

  • SM-13496Drug

    SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6

  • SM-13496Drug

    SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6Time frame: Baseline to 6 weeks

Locations

8 sites in 8 countries. Site status is shown where the registry gives one.

  • Japan 76 sites

    Tokyo, Japan

  • Lithuania 3 sites

    Kaunas, Lithuania

  • Malaysia 5 sites

    Kuala Lumpur, Malaysia

  • Philippines 4 sites

    Manila, Philippines

  • Russia 19 sites

    Moscow, Russia

  • Slovakia 5 sites

    Žilina, Slovakia

  • Taiwan 7 sites

    Taipei, Taiwan

  • Ukraine 9 sites

    Kiev, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.